Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Two-Drug combo speed up delivery after pregnancy loss?

NCT ID NCT05322252

Symptom relief Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether giving two medications (mifepristone and misoprostol) at the same time helps women deliver faster after a nonviable second-trimester pregnancy, compared to misoprostol alone. Thirty women between 14 and 28 weeks pregnant who needed labor induction took part. The goal was to see if more women delivered within 12 hours with the combo, while keeping safety in mind.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mifepristone and misoprostol
What this could lead to
If it works, this could offer a faster, safer way to complete delivery after a nonviable second-trimester pregnancy, reducing infection risk.
What could go wrong
This is a very small pilot study (30 people) with no long-term follow-up. Results may not apply to all situations, and the simultaneous regimen might not be faster or could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

30 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * 14 and 28 weeks' gestation * Singleton gestation * Nonviable fetus (i.e. fetal demise or previable gestational age/weight or lethal fetal anomaly) * Requires induction of labor * If fetal cardiac motion, abortion being performed for medical emergency per MO laws and consents completed Exclusion Criteria: * Contraindication to mifepristone * Plan for surgical evacuation of uterus * Contraindication to vaginal delivery * Plan to initiate induction with any medication or device except misoprostol * Declines participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abortion, second trimester are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fetal Death pregnancy disorder pregnancy disorder with abortive outcome preterm premature rupture of the membranes Rupture, Spontaneous

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abortion, second trimester Fetal death Fetal death before 22 weeks with retention of dead fetus Fetal demise Fetal demise from miscarriage PPROM Pregnancy complications Pregnancy loss Rupture, spontaneous

Contacts and locations

Locations

  • Barnes-Jewish Hospital

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.